Ticker: COHR

Nvidia commits $2 billion each to Lumentum and Coherent, aiming to boost AI processor speeds with advanced photonic tech and expand U.S. manufacturing capacity.

Coherus BioSciences (NASDAQ: COHR) has agreed to sell its Udencya line to Intas Pharmaceuticals for up to $558.4 million, boosting investor confidence as shares rise. Funds will target debt repayment and future growth, with updated financial projections coming in January 2025.